[Evaluation of the effectiveness of hypolipidemic preparations in coronary arteriosclerosis].
Hypolipidemic therapy should be developed as a therapy aimed at the normalization of metabolism since the functional relationship of lipid and carbohydrate metabolism is evident both in normal and pathological conditions. The results of the reaction of the lipid spectrum of the blood to a single glucose load confirms that patients with combined hyperlipoproteinemias (IIb type) are heterogeneous in terms of the pathogenesis of the metabolic disturbances which should be taken into account in assessing the efficiency of hypolipidemic drugs as well as in selecting and administering medicines.
D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation; D005951:Glucose Tolerance Test; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D010840:Phytosterols / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D010840:Phytosterols; D011341:Probucol; C033580:soysterol
Otsenka éffektivnosti gipolipidemicheskikh preparatov pri koronarnom ateroskleroze.